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In response to acute disruption of the permeability barrier of aged mammals there is a diminished capacity for
barrier recovery, analogous to other aged organs when stressed. Acute barrier disruption increases levels of
epidermal cytokines, and cytokines are known regulators of keratinocyte mitogenesis, as well as lipid synthesis in
extracutaneous tissues. Underlying the sluggish barrier recovery in aged skin are diminished mRNA and protein
levels for the interleukin-1 cytokine family, and its receptors. To further elucidate the role of the interleukin-1 family
of cytokines in the barrier repair response, cytokine production was stimulated in aged murine skin with topical
imiquimod application. Imiquimod accelerated barrier recovery after acute insults to aged and young skin. These
functional results correlated temporally with increased interleukin-1a production in the epidermis following topical
imiquimod administration to murine skin. Furthermore, intracutaneous injections of interleukin-1a accelerated
barrier recovery in aged mice. Finally, we showed that interleukin-1a added to cultured human keratinocytes
stimulates epidermal lipid synthesis. These studies provide further evidence for the role of reduced interleukin-1a
signaling in the decline of permeability barrier function in aged skin, and point to the potential use of cytokine
augmentation in barrier dysfunction of the aged.
Key words: epidermis/aging/interleukin-1/imiquimod/permeability barrier/mouse.
J Invest Dermatol 122:330 –336, 2004
Mammalian epidermal permeability barrier, which allows
survival in a terrestrial environment, is dependent upon
robust levels of epidermal lipid synthesis. The epidermal
lipid synthetic apparatus is highly active and relatively
autonomous from circulating influences (Feingold et al,
1983; Mommaas-Kienhuis et al, 1987; Williams et al, 1987).
Yet, epidermal lipid synthesis is regulatable by changes in
permeability barrier function: perturbation of the barrier
results in increased synthesis of all three key lipids
(cholesterol, fatty acids, and ceramides) (Menon et al,
1985; Feingold et al, 1986; Elias and Menon, 1991; Holleran
et al, 1991; Mao-Qiang et al, 1993). These changes in
synthesis can be attributed to antecedent increases in the
activities and mRNA levels of their rate-limiting enzymes
(Proksch et al, 1990; Holleran et al, 1991; Jackson et al,
1992; Harris et al, 1997).
Whereas barrier function appears normal in aged
epidermis under basal, nonstressed conditions, when aged
epidermis is stressed, it reveals decreased stratum cor-
neum (SC) integrity and a diminished capacity for barrier
recovery, analogous to other organs in the aged when
stressed (Ghadially et al, 1995); and superimposition of
photoaging on chronologic aging imposes an additional
stress, with a further decline in barrier function (Reed et al,
1997). The functional abnormality in aged epidermis can be
explained by structural abnormalities in the SC intercellular
lamellar bilayers, attributable to decreased delivery of lipids
to the SC interstices.
As in other aged tissues (Eisenberg et al, 1969), the
structural abnormality can be explained, in turn, by a lipid
abnormality in aged epidermis. In addition to a global
decrease in SC lipid content and synthesis, there is a
profound decrease in cholesterol synthesis (Ghadially et al,
1996). The significance of the cholesterol biosynthetic
abnormality is shown by (1) the ability of topical cholesterol
alone to improve barrier homeostasis in aged skin (Gha-
dially et al, 1996); and (2) the requirement for cholesterol as
the dominant lipid species, when mixtures of the three key
SC lipids are employed together to improve barrier function
in human and murine skin (Zettersten et al, 1997).
More recently, we have assessed the potential role of
defective cytokine signaling as the basis of the barrier
abnormality in aged epidermis. Acute disruption of the
barrier by either acetone treatment or tape stripping, as well
as chronic barrier disruption induced by feeding an
essential fatty acid deficient diet, increase the epidermal
mRNA levels of interleukin-1a (IL-1a), IL-1b, tumor necrosis
factor a (TNFa), and granulocyte-macrophage colony
stimulating factor in young mice, whereas neither IL-6 nor
interferon (IFN) levels change (Wood et al, 1992). Consistent
with these finding.s, in human skin semiquantitative PCR
studies have shown an increase in mRNA for TNFa, as well
as other cytokines/growth factors, following barrier pertur-
bation (Nickoloff and Naidu, 1994). We showed recently that
the levels of IL-1a decrease progressively in aged murine
epidermis, as shown both by immunohistochemistry and
RNAse protection assays (Ye et al, 2002). Furthermore,
Abbreviation: IL-1ra, interleukin 1 receptor antagonist; IL-1a,
interleukin-1a; IFN, interferon; TNFa, tumor necrosis factor a.
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aged epidermis modulates both IL-1a production and IL-1
receptor expression abnormally following barrier perturba-
tion (Ye et al, 2002). These results suggest that cytokines
could signal homeostatic repair responses, and that these
responses may be abnormal in aged skin.
Cytokines alter lipid metabolism in liver and other
tissues. For example, systemic administration of TNFa,
IL-1a, IL-6, and IFNa increase de novo fatty acid and
cholesterol synthesis in liver (Feingold et al, 1989; Grunfeld
et al, 1990). Therefore, the barrier abnormality in aged
epidermis could be due to abnormal cytokine/growth factor
signaling of epidermal lipid synthesis. This hypothesis is
supported by recent studies in transgenic animals. Although
young transgenic animals with single knockouts of the IL-1a
functional (type 1) receptor, TNF functional p55 receptor, or
amphiregulin do not display abnormalities in barrier home-
ostasis (Man et al, 1999), crossbred double knockout
animals reportedly display abnormal barrier recovery after
acute insults (Jensen et al, 1998).1 Moreover, administration
of exogenous TNFa reportedly accelerates barrier recovery
in normal animals (Jensen et al, 1999). More pertinent for
aged skin, we demonstrated recently that (1) aged (22–27
mo) mice with a knockout of the IL-1 receptor type 1 (n¼ 14)
show a significant delay in barrier recovery versus their
aged, wild-type counterparts, and (2) that the barrier defect
appears earlier in knockout mice than in age-matched, wild-
type controls (Ye et al, 2002) or in several other strains of
tested mice. Together, these results further support the
hypothesis that abnormal IL-1 signaling could account for
barrier abnormality in aged animals.
Imiquimod (Aldara, 3M Pharmaceuticals) is an immuno-
modulating agent that has been shown to stimulate
increased IL-1a, TNFa, and IFNg production in cultured
human keratinocytes (Kono et al, 1994; Fujisawa et al,
1996). Moreover, in a recent study of murine skin, IL-6, IL-10,
IFNg, and TNFa expression also increased following a single
topical application of imiquimod (Miller et al, 1998). There-
fore, in these studies we assessed the effects of cytokine
stimulation on barrier homeostasis in aged versus young
murine skin, and determined whether correction of defec-
tive cytokine levels in the aged epidermis correlates with
amelioration of the aged barrier abnormality. We then
determined whether the amelioration of barrier homeostasis
could be attributed to IL-1a stimulation of lipid synthesis.
Results
Topical applications of imiquimod improve permeability
barrier homeostasis in aged murine skin We first
assessed whether topical treatment with imiquimod (10%)
altered the barrier abnormality in aged animals. Imiquimod
(n¼ 7) versus vehicle (n¼5) was applied topically once daily
to aged mouse skin for 7 d prior to acute barrier abrogation.
Although humans occasionally experience skin irritation
with imiquimod we did not see clinical or histologic
evidence of this in the mice. Barrier recovery kinetics were
significantly accelerated in imiquimod- versus vehicle-
treated skin at early time points (Fig 1; po0.01 at 3 h).
These results show that imiquimod pretreatment acceler-
ates the early stages of barrier recovery in aged animals.
IL-1a, but not IL1ra, protein increases after imiquimod
applications to aged animals We next measured IL-1a
and IL-1ra protein levels in aged epidermis, following 7 d of
daily topical imiquimod (10%) versus vehicle application (as
above), using a quantitative ELISA for IL-1a and western
blotting for IL-1ra. The improvement in barrier recovery at 7
d (see above) was paralleled by a 2-fold increase in IL-1a
protein levels in the epidermis of imiquimod- versus vehicle-
treated mice (Fig 2; po0.0005). In contrast, there was no
significant change in IL-1ra levels by western immunoblot-
ting at the same time point (data not shown). These results
show that the improvement in barrier homeostasis that
occurs in aged animals treated with imiquimod treatment
correlates with increased IL-1a levels in the epidermis.
Administration of intracutaneous IL-1a improves barrier
function in aged animals To determine directly whether in
vivo administration of IL-1a improves barrier function, IL-1a
50 ng in 50 mL PBS versus the vehicle alone was injected
intracutaneously into the flanks of aged and young BALB/c
mice (25 mo old (n¼6) versus 6–12 wk old (n¼ 6)). The dose
of IL-1a (50 ng) was chosen because it is comparable to
those employed in prior studies in rodents (Granstein et al,
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Figure1
Topical applications of imiquimod improve permeability barrier
recovery in aged skin. Barrier recovery in control versus treated sites
revealed that imiquimod (n¼ 7), a stimulator of endogenous keratino-
cyte cytokine production (including IL-1a, see Fig 4 below), improves
barrier recovery significantly versus vehicle (n¼ 5) (37% versus 9%
recovery at 3 h, po0.01) when applied topically to aged murine skin
twice daily for 1 wk prior to acute barrier perturbation.
1Jensen J, Kupper T , Proksch E: IL-1a/IL-1a receptor over-
expression and knockout constructs in permeability barrier repair
of transgenic mice. J Invest Dermatol 110:499, 1998 (abstr)
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1986). Because of possible systemic effects of the
intracutaneous IL-1a, separate mice were used for IL-1a-
treated and vehicle-treated groups. The barrier was
perturbed by tape stripping immediately following the
injection, and barrier recovery rates were compared as
above. Barrier recovery kinetics accelerated significantly in
both IL-1a-treated young and aged mice versus vehicle-
treated controls, but the extent of improvement was greater
in aged animals, remaining significant to at least 24 h post-
IL-1a administration (Fig 3a, b). These results show that
exogenous IL-1a accelerates epidermal permeability barrier
recovery in both aged and young mice, with more
significant improvement in aged skin.
IL-1a treatment normalizes lamellar bilayer structure in
aged epidermis Prior studies have shown that the barrier
abnormality in aged mice is associated with reduced
numbers of lamellar bodies, decreased secreted lamellar
body contents, and patchy reductions in extracellular
lamellar bilayers (Ghadially et al, 1995). As the most marked
acceleration in barrier recovery is apparent 3–6 h after IL-1a
administration, we compared the lamellar body secretory
system and SC morphology at these time points. As seen in
Fig 4, IL-1a treatment increased the density of lamellar
bodies in the cytosol of cells in the outer stratum
granulosum, as well as the amounts of secreted organelle
contents at the stratum granulosum–SC interface. More-
over, whereas vehicle-treated, aged epidermis displayed
little or no return of extracellular lamellar bilayers, IL-1a-
treated samples displayed bilayer quantities comparable to
young murine skin at comparable time points after barrier
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Figure 2
The improvement in barrier recovery with topical imiquimod is
associated with increased epidermal IL-1a expression. Imiquimod,
applied topically to aged murine skin twice daily for 1 wk prior to barrier
perturbation, doubled epidermal IL-1a protein levels by ELISA
(po0.0005), but did not change IL-1ra levels by western blotting (not
shown).
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Figure3
Administration of intracutaneous IL-1a improves barrier function in
young and aged mice. IL-1a versus vehicle alone was injected
intracutaneously into the flanks of young (A) and aged (B) BALB/c mice
(6–12 wk old (n¼ 6) versus 25 mo old (n¼6)) 5 min prior to barrier
perturbation. In both young and aged mice, the IL-1a-treated mice
versus vehicle-treated mice exhibited a significant improvement in
barrier recovery, although the improvement in young mice was not as
pronounced as in the aged.
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Comparison of results in Fig 3(A), (B). Although no statistical analysis
is possible as these are separate experiments, it can be seen that
following imiquimod application aged barrier recovery is improved,
such that, especially at early time points, barrier recovery in imiquimod-
treated aged skin is comparable to that of untreated young skin.
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disruption (Fig 5; see also Ghadially et al, 1995). Finally, the
number of lamellar bodies was increased in IL-1a-treated
samples (Fig 5; see also Ghadially et al, 1995). Together,
these results demonstrate that the IL-1a-stimulated accel-
eration of barrier recovery is paralleled by a normalization of
the lamellar body secretory system and its resultant bilayers
in aged epidermis.
IL-1a increases lipid synthesis in cultured human
keratinocytes Because of the limited availability of aged
mice, we performed further mechanistic studies in cultured
keratinocytes. To determine whether the IL-1a-stimulated
increase in lamellar body secretion reflects increased lipid
synthesis, we next assessed whether exogenous IL-1a
directly stimulates keratinocyte lipid production in cultured
human keratinocytes. IL-1a (10 ng per mL) or vehicle alone
was added to second passage, cultured human keratino-
cytes (n¼6), grown under serum- and growth-factor-free
conditions for the prior 24 h. After 24 h total lipid synthesis
increased by approximately 25% in IL-1a-treated cultured
human keratinocytes (p¼ 0.002). Synthesis of both non-
saponifiable and saponifiable lipids was increased signifi-
cantly (41%, p¼ 0.00, and 16%, p¼ 0.02, respectively)
(Fig 6). These results show that exogenous IL-1a directly
stimulates lipid synthesis in cultured keratinocytes, corre-
lating with both increased lamellar body production and
barrier recovery in cytokine-treated, aged tissues.
Discussion
Whereas permeability barrier function is normal under
basal, nonstressed conditions, aged epidermis displays
delayed barrier recovery kinetics when it is subjected to
stress, analogous to the diminished reparative capacity of
other organs in the aged (Ghadially et al, 1995). Further-
more, superimposition of photoaging produces an addi-
tional delay in barrier recovery (Reed et al, 1997). The basis
Figure 5
IL-1a treatment augments lamellar
body formation and secretory re-
sponse in aged murine skin: (A)
vehicle treated (Veh); (B), (C) IL-1a
treated. Three hours after acute bar-
rier disruption, IL-1a-treated sites re-
veal enhanced secreted material (B,
arrows) at the stratum granulosum–SC
interface in comparison to secreted
material in vehicle-treated sites (A,
open arrows). (C) The number of
lamellar bodies (arrowheads) in the
cytosol of outer stratum granulosum
cells is greatly increased in IL-1a-
treated versus vehicle-treated epider-
mis (not shown; see Ghadially et al,
1995). (A), (B) Ruthenium tetroxide
postfixation; (C) osmium tetroxide
postfixation. Magnification bar: (A)(C)
0.25 mm.
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for the barrier abnormality in aged epidermis is a decrease
in the quantities of SC extracellular bilayers, attributable to
decreased secreted lipid at the SC–stratum granulosum
interface, and a global decrease in SC lipid content
(Ghadially et al, 1996). The metabolic basis for the
structural/functional abnormality is a decrease in the
synthesis of cholesterol, fatty acids, and ceramides, which
are destined for lamellar bilayer formation (Ghadially et al,
1996). The most profound alterations occur in cholesterol
synthesis, however, as well as in 3-hydroxy-3-methylglutar-
yl-coenzyme A reductase activity. These studies suggest
that the barrier abnormalities in aged epidermis can be
attributed to a failure to synthesize and deliver sufficient
lamellar-body-derived lipids to the SC interstices. As topi-
cally applied, physiologic lipids incorporate directly into
nascent lamellar bodies, bypassing the synthetic apparatus,
they have the potential of ameliorating the barrier abnorm-
ality in aged epidermis. Indeed, a single topical application
of cholesterol alone, or an equimolar mixture of the three key
SC lipid classes, improves barrier recovery in aged murine
skin, and applications of cholesterol-dominant mixtures of
these three lipids further normalize barrier recovery in aged
murine and human skin (Zettersten et al, 1997).
In recent studies, we showed that expression of the IL-1
family of proteins and its receptors is abnormal in aging
epidermis (Ye et al, 2002). Prior work has also shown that
IL-1a levels decrease in primary keratinocyte cultures of
aged human epidermis (Sauder et al, 1988), and that mRNA
levels for IL-1a reportedly decrease in aged murine
epidermis (Sauder et al, 1989). In contrast, IL-1ra mRNA
increases in primary cultures from aged human epidermis,
with a lesser increase in keratinocytes from photoaged
human epidermis (Garmyn et al, 1992; Gilchrest et al, 1994).
Based upon this work, we assessed whether modulation of
IL-1a levels, either by administration of immumodulatory
agents or by direct administration of exogenous IL-1a would
improve barrier recovery. Barrier recovery was improved
with imiquimod administration to aged murine skin. As
imiquimod produces alterations in multiple cytokine path-
ways, we next proceeded to show that imiquimod admin-
istration increases IL-1a levels in aged epidermis.
Indeed, imiquimod administration did increase IL-1a 2-
fold, and IL-1a was most effective at improving barrier
recovery in aged skin, such that the rate of barrier recovery
approached that of young control skin. IL-1a was also able
to increase significantly the barrier recovery in young skin,
although not as dramatically as in aged skin. This would be
expected because aged skin is known to start out with a
deficit in IL-1a and barrier recovery (Ye et al, 2002).
Barrier recovery of the epidermis is associated with an
increase in lipid synthesis of barrier associated lipids. IL-1a
administration resulted in increased lipid synthesis in
cultured human keratinocytes. The greatest increase was
in the more profoundly defective lipid (in human epidermis),
cholesterol.
Cytokines alter lipid metabolism in liver and other
tissues. For example, systemic TNFa, IL-1a, IL-6, and IFNa
increase de novo fatty acid and cholesterol synthesis in liver
by increasing hepatic levels of citrate, an allosteric activator
of acetyl coenzyme A carboxylase, a key enzyme in fatty
acid synthesis. More recently, it was shown that TNF and IL-
1a stimulate ceramide synthesis, and serine palmitoyl
transferase mRNA and enzyme levels, in hepatocytes. Most
importantly, it was shown that IL-1a stimulates cholesterol
synthesis and 3-hydroxy-3-methylglutaryl-coenzyme A re-
ductase in hepatocytes. Although there are no studies of
IL-1a regulation of SREBP, an interleukin-1b converting
enzyme-related cysteine protease that cleaves SREBP
between the leucine zipper and transmembrane domains
has previously been purified. Also, TNF and IL-6 have been
shown to activate SREBP. These findings suggest that
cytokines could regulate lipid synthesis through activation
of SREBP.
In summary, we have shown that immunomodulation of
IL-1a levels improves barrier function in aged epidermis.
The ability of imiquimod applied topically, and IL-1a
administered intracutaneously, to improve barrier recovery
in the epidermis of aged mice, and the ability of cytokines to
increase lipid synthesis in keratinocytes, provide further
evidence for the role of cytokine alterations in the decline in
aged barrier function, and suggest a new form of therapy for
aged skin.
Materials and Methods
Animals Outbred hairless mice CrL:SKHI (hr/hr) BR (Charles River
Laboratories, Wilmington, MA) comprised the murine model. The
aged mice were 18–24 mo old. The young mice were 6–10 wk old.
Aged mice were checked regularly for microbial diseases and
tumors. Mice that showed evidence of either systemic illness or
tumor development were not studied. Institutional approval was
obtained prior to all studies.
Barrier disruption and tissue harvesting Barrier abrogation in all
experiments was achieved by sequential applications of cello-
phane tape (six to eight times). The procedure was stopped when
the transepidermal water loss reached 6–10 mg per cm2 per h as
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Figure 6
Basis for improved barrier: IL-1a added to cultured human
keratinocytes results in increased synthesis of barrier lipids.
Addition of 10 ng per mL IL-1a to cultured human keratinocytes
(n¼ 6) resulted in a 23% increase in total lipid synthesis (p¼0.002).
Although both nonsaponifiable (NS) and saponifiable (S) lipids
increased significantly (41%, p ¼ 0, and 16%, p¼0.02, respectively),
the most dramatic increase was in NS lipids (primarily cholesterol).
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measured with an electrolytic water analyzer (Meeco, Warrington,
PA). Control mice were untreated. It has been found previously that
untreated mice, as well as those treated with sterile endotoxin-free
saline, exhibit identical baseline levels of epidermal cytokines
(Wood et al, 1992). Samples for ELISA and western blot studies
were obtained immediately prior and 3 h following barrier
disruption. Skin excised from the treated area (entire torso) was
placed epidermis side downward on plastic Petri dishes. Sub-
cutaneous fat was removed with a scalpel, and skin was then
floated epidermis upward on 10 mL of 10 mM ethylenediamine
tetraacetic acid (EDTA) in Ca, Mg-free phosphate-buffered saline
(PBS). Incubations were continued at 371C for 35 min in order to
separate the epidermis from the dermis (Menon et al, 1985;
Grubauer et al, 1987). Epidermis was scraped off the underlying
dermis with a scalpel and kept at 701C until proteins were
isolated (see below).
Imiquimod applications In studies on barrier homeostasis, we
assessed whether topical treatment with 10% imiquimod in
propyleneglycol:propanol (7:3, vol/vol) (3M Pharmaceuticals, St
Paul, MN) improved the aged barrier abnormality. Imiquimod 10%
(n¼ 7) versus propylene glycol:propanol vehicle (n¼ 5) was applied
once daily topically to aged (18–24 mo) mouse skin for 4–7 d prior
to barrier abrogation. Barrier recovery kinetics were then assessed,
and ELISA and western blot studies were performed on samples
obtained just prior to barrier abrogation (see below).
IL-1a administration To determine whether cytokine administra-
tion improves barrier function in vivo, IL-1a (50 ng in 50 mL PBS) or
PBS (50 mL) alone was injected intradermally into the flanks of aged
(25 mo, n¼ 6) and young (8–12 wk, n¼ 6) BALB/c mice (Granstein
et al, 1986; Enk et al, 1993; Lee et al, 1994). Mice were shaved 3–4
d prior to barrier perturbation. The barrier was perturbed
immediately after and barrier recovery was monitored. Samples
were taken 3 h post barrier perturbation for electron microscopy
(see below). For studies in cultured human keratinocytes IL-1a (10
ng per mL) or vehicle alone was added to the culture medium for
3 h before harvesting for lipid synthesis studies (see below).
Results were then assessed using a Student’s unpaired t test.
ELISA IL-1a protein concentrations were quantitated by ELISA,
using the Quantikine Mouse IL-1a Immunoassay kit (R&D Systems,
Minneapolis, MN) according to the manufacturer’s directions. All
samples were assayed in duplicate. 2.5 ng of protein was used for
each sample well. ELISA results were analyzed on an Emetic
microplate reader (Molecular Devices, Sunnyvale, CA). Results
were compared in imiquimod-treated versus vehicle-treated
epidermis using an unpaired Student’s t test.
Western blotting The levels of murine IL-1 receptor antagonist
(IL-1ra) protein in mouse epidermis was analyzed by Western
immune blotting. The frozen epidermis, obtained from one mouse
flank, was homogenized on ice in a polytron (Kinematica, Littau/
Lucerne, Switzerland), for 30 s, in 3 mL of 2  sample loading
buffer (100 mM Tris Cl, 200 mM dithiothreitol, 4% sodium dodecyl
sulfate, 20% glycerol, 0.1% b-mercaptoethanol, 0.2% bromophe-
nol blue). 25 mg of each sample in 1  sample loading buffer was
loaded onto a 15% sodium dodecyl sulfate polyacrylamide gel
(Bio-Rad, Hercules, CA). After electrophoresis one gel was used for
transfer onto nitrocellulose membrane (Bio-Rad, Hercules, CA)
(Burnette, 1981), and another parallel gel was used for staining with
Coomassie Blue to check for sample loading equivalence.
Immunoblotting was performed with SuperSignal West Dura
Extended Duration Substrate (Pierce, Rockford, IL). Primary
antibody was goat antimouse IL-1ra (R&D Systems) used at 0.1
mg per mL. The secondary antibody was horseradish-peroxidase-
conjugated affinity purified mouse antigoat IgG (Hþ L) (Jackson
ImmunoResearch Laboratories, Western Grove, PA) used at 0.04
mg per mL. The band of IL-1ra on Kodak BIOMAX MR film was
scanned by a densitometer (E-C Apparatus, St Petersburg, FL).
Electron microscopy Biopsy specimens from aged mice 3 h after
barrier disruption, IL-1a treated versus vehicle treated, were
processed for electron microscopy. Samples were cut in pieces
1 mm3 or smaller and fixed overnight at 41C in 2% glutaraldehyde,
2% paraformaldehyde with 0.06% calcium chloride in 0.1 mol per
L sodium cacodylate buffer, pH 7.3. Specimens were then washed
in 0.1 mol per L sodium cacodylate buffer before further
processing. Tissue sections were placed in either (1) 0.2%
ruthenium tetroxide (Polysciences, Warrington, PA) with 0.5%
potassium ferrocyanide in 0.1 mol per L sodium cacodylate, pH
7.4, at room temperature in the dark for 0.5 h, or (2) 1% osmium
tetroxide with potassium ferrocyanide (1.5%) in 0.1 mol per L
sodium cacodylate at room temperature in the dark for 1 h. After
rinsing in cacodylate buffer, tissue samples were dehydrated in a
graded ethanol series and subsequently embedded in a low
viscosity epoxy resin containing DER 736 and Epon 812. Thin
sections were examined both unstained and/or after staining with
uranyl acetate and lead citrate in a Zeiss 10 A electron mcroscope.
Lipid synthesis Neonatal human keratinocytes were obtained in
accordance with Declaration of Helsinki Guidelines; they were
grown in KGM (Clonetics) with 0.07 mM CaCl2 to 90% confluence
and then changed to KGM with 1.2 mM CaCl2 for 24 h until 100%
confluent. Subsequently, they were changed to KBM (no growth
factors) with 1.2 mM CaCl2 for 18 h before experimentation.
Medium was then changed to fresh KBMþ 1.2 mM CaCl2þ 1 mM
sodium acetate  IL-1a 10 ng per mL; the cultures were incubated
for 90 min, and then 14C-acetate (American Radio Chemicals, 56.7
mCi per mmol) was added (8.385 mCi per mL). Cultures were
incubated for 2 h at 371C and then harvested; and saponifiable
lipids were extracted separately and counted on a Beckman LS
1800 liquid scintillation counter.
Full-thickness skin was collected, the fat was scraped away, the
total surface area recorded, and the skin was floated in KBM
without CaCl2, plus 10 mM EDTA, 1 mM sodium acetate, and 16.88
mCi per mL 14C-acetate. Full-thickness skin samples were
incubated 2 h at 371C, rinsed with distilled H2O, and the epidermis
was peeled off and saponified as above. Total, saponified, and
nonsaponified lipids were then assessed in IL-1a versus control
samples, using an unpaired Student’s t test.
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